Carnitine palmitoyltransferase II deficiency

Marcus Deschauer MD

Neurogenetic Disorders

Updated 03.22.2024
Released 03.30.1995
Expires For CME 03.22.2027

Carnitine palmitoyltransferase II deficiency

Author: Marcus Deschauer MD

See Contributor Disclosures

Editor: Deepa S Rajan MD

Carnitine palmitoyltransferase II deficiency

In This Article

Quick Link

Introduction

Overview

Carnitine palmitoyltransferase II deficiency is the most frequent hereditary disorder of fatty acid metabolism affecting muscle. The clinical hallmark of the muscle form are exercise-induced attacks of rhabdomyolysis. Less frequently, a severe infantile form with liver failure and hypoketotic hypoglycemia occurs. The author summarizes the clinical features of the disease and the search for an effective treatment that is still lacking.

Key points

	• Carnitine palmitoyltransferase II deficiency frequently manifests with episodes of rhabdomyolysis after prolonged exercise and fasting leading to myoglobinuria and myalgia.
	• This muscle form of the disease is the most frequent cause of hereditary myoglobinuria.
	• A severe infantile form with liver failure and hypoketotic hypoglycemia and a lethal neonatal form represent other rarer manifestations.
	• Analysis of acylcarnitine profile in blood by tandem mass spectrometry that is used in newborn screening is helpful to identify patients in later life.
	• High intake of carbohydrate is recommended before exercise to prevent episodes of rhabdomyolysis.

Historical note and terminology

Carnitine palmitoyltransferase II deficiency is an inherited disorder of lipid metabolism affecting the entry of long-chain fatty acids into mitochondria. It was the first enzyme defect of fatty-acid oxidation to be discovered. In 1973, DiMauro and Melis-DiMauro described this enzyme defect in two brothers suffering from recurrent episodes of muscle pain and pigmenturia with occasional renal failure. The recurrent attacks were triggered by prolonged exercise, especially when the patient fasted (15). Several hundred patients have since been reported worldwide, and it has been clearly established that the defective enzyme is carnitine palmitoyltransferase II, the inner mitochondrial membrane component of the carnitine palmitoyltransferase system. Deficiency of the outer mitochondrial membrane component of the system, carnitine palmitoyltransferase I, was discovered in 1981 in a young girl with a pure "hepatic" presentation characterized by morning seizures due to fasting hypoglycemia (09).

Although exercise-induced recurrent myoglobinuria remains the most common manifestation of carnitine palmitoyltransferase II deficiency, other multisystemic phenotypes have been ascribed to a defect of this enzyme. Severe or lethal early-onset forms have been reported in neonates (30) and children (10) who present with hypoketotic hypoglycemia, liver failure, cardiomyopathy, generalized steatosis, developmental abnormalities, and early death.

In 1991 the human carnitine palmitoyltransferase II cDNA was cloned (25), and 1 year later, the first mutation in a patient with carnitine palmitoyltransferase II deficiency was identified (59).

Clinical manifestations

Presentation and course

Despite the apparent coordinated function of carnitine palmitoyltransferase I and carnitine palmitoyltransferase II in all tissues, the clinical manifestations of deficiencies of the two enzymes generally differ. Carnitine palmitoyltransferase I deficiency is commonly referred to as the hepatic form of carnitine palmitoyltransferase deficiency. This disease is discussed in a separate article. Although carnitine palmitoyltransferase II exists only in one isoform across various tissues, there are three different phenotypes of carnitine palmitoyltransferase II deficiency that are inherited as an autosomal recessive trait. There is a muscle form that presents in childhood or adulthood, a multisystemic infantile form, and a lethal neonatal form with congenital malformations.

Muscle form (OMIM 255110). This form is the most common disorder of lipid muscle metabolism and the most frequent cause of hereditary myoglobinuria (63). Typically, it presents with attacks of exercise induced muscle pain with rhabdomyolysis and myoglobinuria (72). But myoglobinuria with brown-colored urine, the clinical hallmark of muscle carnitine palmitoyltransferase II deficiency (16), is absent in 10% to 20% of the patients (41; 13; 33). Myalgia is the most frequent symptom reported by nearly all carnitine palmitoyltransferase II deficient patients (13; 33; 35), but only a few patients complain of muscle cramps. Instead, patients describe a feeling of "tightness" and pain in the exercising limb or trunk muscles before the appearance of myoglobinuria. This can impair daily activities. Many patients complain of subjective muscle weakness during the attacks (13; 35).

The severity of the attacks can be highly variable and 20% of the patients suffer from life-threatening rhabdomyolysis requiring dialysis (13; 33). Respiratory failure due to muscle weakness and paroxysmal dysrhythmias are also life-threatening complications that rarely occur (62; 53). Frequency of attacks ranges from one attack to dozens of attacks per year (35). Between the attacks, persistent weakness is uncommon and was communicated only in single cases (16; 28).

Although carnitine palmitoyltransferase II deficiency is evident in other tissues (eg, liver, leukocytes, fibroblasts), extramuscular manifestations are typically not present.

Typically, the attacks occur after prolonged exercise. In some patients, symptoms were induced only by heavy or long-term exercise such as mountain hiking; in others, symptoms resulted after mild exercise such as strolling. Unlike patients with glycolytic defects, patients with carnitine palmitoyltransferase II deficiency do not show reduced tolerance to brief strenuous exercise, do not experience a "second-wind" phenomenon (switch to utilization of fatty acids), and may not feel premonitory symptoms. Exercise is a relevant trigger in 90% of patients (13; 33). Another frequent trigger is fasting or low nutritional intake. Sometimes infections, cold temperatures, and even emotional stress can trigger attacks (13; 33). Often, attacks were induced by a combination of triggers (eg, extensive skiing in the cold without appropriate food intake). Moreover, there are few reports that attacks could be triggered by drugs like ibuprofen (50), high doses of diazepam (02), valproate (38), or by general anesthesia (36). Sometimes, however, there is no apparent cause for the rhabdomyolysis.

The first episode usually occurs in childhood or adolescence but not in infancy. In approximately 50% of the patients, the first attack occurred in childhood (33); thus, the term “adult” carnitine palmitoyltransferase II deficiency for the muscle form in contrast to “infantile” carnitine palmitoyltransferase II deficiency for the multisystemic form can be misleading.

A male predominance (68% to 86%) was reported in several studies (72; 07; 41; 13; 33). But it remains unknown if this is due to gender-related differences in exercise activities, a modifier gene on the X chromosome, or hormonal factors, such as estrogen.

Multisystemic infantile form (OMIM 600649). This less common form of carnitine palmitoyltransferase II deficiency is sometimes referred to as the "hepato-cardio-muscular" form. It is characterized by recurrent attacks of acute liver failure with hypoketotic hypoglycemia and cardiac arrhythmias. Age of onset ranges from 3 months to 2 years. Parental consanguinity is often observed. Frequently, there is a family history of unexpected death in infants following a Reye-like episode. Carnitine palmitoyltransferase II deficiency was also diagnosed postmortem in patients with sudden infant death (70). The disease always manifests with lethargy and encephalopathy as consequences of hypoketotic hypoglycemia. As is usually observed in this group of disorders, fasting and febrile infection are trigger factors. Hepatomegaly is always present. Signs of cardiac involvement are found in most cases. Although cardiomyopathy is the usual expression of heart injury in other disorders of fatty-acid oxidation, patients with the infantile form of carnitine palmitoyltransferase II deficiency characteristically exhibit dysrhythmias with or without cardiomegaly. Skeletal-muscle involvement is usually restricted to a mild increase in serum creatine kinase levels and can be demonstrated by histological examination. Muscle tone may be reduced, and patients may suffer of muscle weakness. However, rhabdomyolysis and myoglobinuria are rarely observed (10; 07; 08).

Lethal neonatal form (OMIM 608836). This is the most severe form of carnitine palmitoyltransferase II deficiency. It is commonly associated with congenital anomalies. Affected neonates present at birth with profound metabolic decompensation characterized by hypoketotic hypoglycemia, hyperammonemia, metabolic acidosis, respiratory distress, hepatomegaly, and cardiomegaly. Cardiac resuscitation is often required. Hypotonia and hyperreflexia, as well as generalized seizures, may develop. There appears to be no variability within families, as affected siblings exhibit the same clinical phenotype and pathologic changes. Most patients die during the first month of life because of the occurrence of hepatic and renal failure, cardiac arrhythmias, and infection. Hepatic steatosis is a constant feature (08). Brain abnormalities (polymicrogyria and hemorrhages) and dysmorphic features are common, and enlarged kidneys with bilateral multiple congenital cysts, which have been described in all but one case (30; 04), are a distinctive finding in this disorder.

Prognosis and complications

Muscle form. The muscle form of carnitine palmitoyltransferase II deficiency is usually a benign disease with a favorable evolution. Except for during episodes of myoglobinuria, muscle strength and serum creatine kinase level are normal. Patients usually have an excellent long-term prognosis. In many cases, after the diagnosis is made, attacks can be effectively prevented by dietary regimen and extra carbohydrate intake during prolonged exercise or other situations that can provoke rhabdomyolysis (51).

Acute tubular necrosis, as a result of massive myoglobinuria, is the only life-threatening complication. Although renal failure has been documented in approximately 20% of patients, if it is promptly recognized and appropriately treated, a complete recovery should be expected in virtually all cases. Cardiac arrest can occur during an attack, and a single case has been reported with a fatal outcome (37).

Multisystemic form. The clinical course is not benign because of the occurrence of life-threatening cardiac dysrhythmias and the neurologic sequelae of hypoglycemic episodes, such as severe static encephalopathy with spastic paraplegia or psychomotor developmental delay (22). There are several reports of sudden death (10; 03). However, patients with survival up to 20 years were also reported (42; 08).

Lethal neonatal form. The prognosis is severe due to infections and cardiac and renal complications. There is no patient known who survived longer than 1 month.

Clinical vignette

A 25-year-old man reported that he developed muscle pain and weakness after exercise beginning at age 19. At age 23 he was hospitalized for the first time because of severe muscle weakness and muscle pain after playing football. There was severe rhabdomyolysis that required dialysis. Four months later, he developed identical symptoms during an upper respiratory illness and, at age 24, after practicing sports excessively. Neither his parents nor other family members exhibited similar symptoms. Neurologic examination between the attacks was normal. During all episodes, creatine kinase was elevated (up to 42,000 IU/l) but returned to normal after the attack. Histological analysis of a muscle biopsy was normal, but biochemical analysis of the biopsy and molecular genetic investigation revealed carnitine palmitoyltransferase II deficiency (12).

Biological basis

Etiology and pathogenesis

Carnitine palmitoyltransferase II deficiency is an autosomal recessive inherited disorder of lipid metabolism. Pathogenic variants in the carnitine palmitoyltransferase II gene result in a defective carnitine palmitoyltransferase II enzyme (EC 2.3.1.21). This enzyme is part of the carnitine shuttle system that is responsible for the transport of long-chain fatty-acids into mitochondria. Thus, beta-oxidation of long-chain fatty-acids is altered in carnitine palmitoyltransferase II deficiency.

Biochemical basis. In contrast to short-chain and medium-chain fatty-acid esters (acyl-CoAs), long-chain acyl-CoAs (C14 to C20) cannot enter mitochondria directly. As the inner mitochondrial membrane is impermeable to long-chain acyl-CoAs, but not to their carnitine esters, a long-chain acyl-CoA must be transesterified by carnitine palmitoyltransferase I to form a long-chain fatty acylcarnitine. Carnitine and acylcarnitine translocase then carry the acylcarnitine across the barrier of the inner mitochondrial membrane in exchange for free carnitine. Finally, on the matrix side of the inner mitochondrial membrane, a second transesterification reaction catalyzed by carnitine palmitoyltransferase II generates matrix long-chain acyl-CoAs that enter the mitochondrial beta-oxidation. Carnitine palmitoyltransferase I is located on the inner side of the outer mitochondrial membrane, is specifically inhibited by malonyl-CoA, and loses activity on exposure of mitochondria to strong detergents. By contrast, carnitine palmitoyltransferase II is located on the inner mitochondrial membrane, is insensitive to malonyl-CoA inhibition, and is released in active form on exposure of mitochondria to a variety of detergents (69).

Mitochondrial beta-oxidation of long-chain fatty acid is a major source for energy production particularly at times of stress or fasting. Long-chain fatty acid oxidation contributes to energy homeostasis especially in the heart, the liver, and the skeletal muscle. In the liver, oxidation of long-chain fatty acids produces ketone bodies (which provide auxiliary fuel for nonhepatic tissues) and enhances gluconeogenesis. Therefore, hepatic fatty acid oxidation contributes to energy homeostasis during fasting. Skeletal muscle can use carbohydrates or lipids as fuel, depending on the degree of activity. During the early phase of exercise (up to approximately 45 minutes), energy is derived mainly from blood glucose and muscle glycogen metabolism. During prolonged exercise, there is a gradual shift from glucose to fatty-acid utilization. After a few hours of exercise, about 70% of the skeletal-muscle energy requirement is met by the oxidation of long-chain fatty acids.

Carnitine palmitoyltransferase II deficiency makes long-chain fatty acids unavailable for use by the mitochondria. The vulnerability of muscle to the metabolic block depends on the activity level of the muscle. When patients with carnitine palmitoyltransferase II deficiency exercise for prolonged periods, glycogen stores may be exhausted, and rhabdomyolysis may occur. In patients with the muscle form of carnitine palmitoyltransferase II deficiency, oxidation of long-chain fatty acids was normal at rest but impaired during prolonged exercise (45). Fasting worsens the situation because it reduces the availability of both muscle glycogen and blood glucose, further increasing the dependence of muscle on fatty-acid metabolism. In some cases, reduced hepatic production of ketone bodies deprives muscle of another alternative fuel. Reduced availability of alternative energy sources and/or increased dependence on lipid oxidation may predispose to metabolic crises. Thus, cold exposure may be deleterious because of impaired ketogenesis (which, in unaffected individuals, is stimulated by exposures to low temperatures) and shivering, which is an involuntary form of muscle activity particularly dependent on long-chain fatty acid oxidation. Infection probably acts by inducing an abnormally increased dependence on lipid metabolism. The biochemical pathogenesis of myoglobinuria might be explained by the inability to utilize fatty acids as an alternative energy source for the production of the ATP needed to maintain sarcolemmal integrity.

Other symptoms observed in the more severe early-onset forms may be explained by defective energy production. Hypoglycemia, characteristically accompanied by hypoketosis that occurs in affected individuals during fasting, can be caused by (1) an increase in peripheral glucose utilization because of the deficient production of ketone bodies and (2) impaired acetyl-CoA synthesis that typically stimulates gluconeogenesis via allosteric activation of pyruvate carboxylase. Possible pathogenetic mechanisms for the development of cardiomyopathy and sudden death in patients with early-onset carnitine palmitoyltransferase II deficiency include both inadequate energy supply in the heart and myocardial damage and arrhythmogenesis due to the toxic effects of elevated intracellular concentration of acylcarnitines. Long-chain acylcarnitines, which are known to cause myocardial injury and rhythm disturbances during myocardial ischemia and infarction, are thought to promote arrhythmogenesis via direct activation of Ca2+ channels (44). Association of congenital anomalies with prenatal energy deprivation is observed in a number of inborn errors of metabolism (eg, multiple acyl-CoA dehydrogenase deficiency, fumarase deficiency).

The distinct metabolic and clinical consequences of carnitine palmitoyltransferase II deficiency observed in the early-onset multisystemic and late-onset muscle forms of the disease might depend in part on the magnitude of carnitine palmitoyltransferase II residual activity (10). As a matter of fact, a nonlinear relationship between carnitine palmitoyltransferase II activity and long-chain fatty acid oxidation has been observed in fibroblasts. As compared with controls, a residual activity lower than 10% found in the early-onset cases resulted in a greater than 90% decrease of palmitate oxidation, whereas a residual activity higher than 15% found in the adult-onset cases maintained palmitate oxidation above 50%. Nothing is known concerning the level of carnitine palmitoyltransferase II activity necessary to maintain normal long-chain fatty acid oxidation in tissues other than fibroblasts, namely the liver, heart, and skeletal muscle. This threshold activity could vary among tissues. Thus, the residual carnitine palmitoyltransferase II activity found in the adult-onset form of the disease would be rate-limiting for long-chain fatty acid oxidation only in skeletal muscle. Carnitine palmitoyltransferase II activity that is reduced more, as in the early-onset forms of the disease, impairs long-chain fatty acid oxidation not only in skeletal muscle but also in heart, liver, and kidney. This may account for the multiorgan involvement in the neonatal form of the disease.

Molecular genetic basis. The human carnitine palmitoyltransferase II gene is located in chromosome 1p32 (26). Around 100 disease-causing variants have been identified to date. Some variants are recurrent, but most are identified only in single patients. Missense variants and truncating variants in all exons and some splice-site variants have been identified (23; 33). Important clues for genotype-phenotype correlations in carnitine palmitoyltransferase II deficiency exist. For example, less severe missense variants are associated with the muscle form of the disease, and some “severe” truncating variants are associated with the multisystemic infantile or lethal neonatal form if they are present in homozygous state. However, the correlation is not perfect because one variant (p.R631C) has been identified in the multisystemic infantile form and in the muscle form in homozygous state (07).The lethal neonatal form is frequently associated with truncating variants on both alleles (21; 67). Compound heterozygosity for a “mild” and a “severe” variant can be associated either with the relatively mild muscle form or with the severe multisystemic infantile form (07; 67). Finally, symptomatic individuals with a variant on one allele only have been reported (56; 45; 32; 23; 34). Biochemical investigations in these individuals revealed intermediate activities (34), and in-vivo oxidation of long-chain fatty acids was impaired (45).

In Caucasian patients with the muscle form, a common variant (p.S113L) is identified in 60% to 70% of mutant alleles (58; 13). This variant was never observed in patients with the multisystemic or lethal form. In contrast to the muscle form, there is no common variant in the lethal neonatal or multisystemic infantile form. The p.P50H is a less frequent variant that identified in 5% of the alleles in patients with muscle carnitine palmitoyltransferase II deficiency (56; 61; 13; 33). The c.1238delAG variant, associated with different forms of CPT II deficiency, is known to be of Ashkenazi Jewish origin (13; 21; 33; 56). In Japan there is a distinct frequent variant p.F383Y in patients with carnitine palmitoyltransferase II deficiency (71).

Differential diagnosis

The differential diagnosis of the muscle form of carnitine palmitoyltransferase II deficiency is mainly that of myoglobinuria and exercise-induced myalgia. Although recurrent myoglobinuria is a characteristic of a number of inherited metabolic myopathies (60; 63), it is also a symptom common to several different disorders including strenuous exercise, chronic alcoholism, toxic agents (especially drugs such as statins or fibrates), infections, trauma, and other genetic diseases, such as muscular dystrophy or malignant hyperthermia.

Carnitine palmitoyltransferase II deficiency is the most common identifiable metabolic cause of myoglobinuria, followed by myophosphorylase deficiency (glycogenosis type V) (63). Some other rarer defects of glycogen metabolism can cause “pure” myoglobinuria also. Other fatty acid oxidation disorders are important to consider in the differential diagnosis. For example, symptoms of very-long-chain acyl-CoA dehydrogenase deficiency are similar to those of carnitine palmitoyltransferase II deficiency. Also, variants in the ryanodine receptor 1 gene can result in exercise-induced rhabdomyolysis. Finally, there are several patients with mitochondrial variants due to mutations in mitochondrial DNA and patients with treatable coenzyme Q deficiency who have presented with myoglobinuria.

The differential diagnosis of multisystemic carnitine palmitoyltransferase II deficiency primarily includes other genetic defects of fatty-acid oxidation. Many of these defects are similar, presenting with hypoketotic hypoglycemia and heart and skeletal-muscle involvement: Deficiency of carnitine, carnitine and acylcarnitine translocase, trifunctional protein, very long-chain and long-chain acyl-CoA dehydrogenases, short-chain 3-hydroxyacyl-CoA dehydrogenase, and multiple acyl-CoA dehydrogenase deficiency. Characteristically, cardiomyopathy and myopathy are never observed in carnitine palmitoyltransferase I deficiency and medium-chain acyl-CoA dehydrogenase deficiency. Other multisystemic mitochondrial disorders affecting oxidative phosphorylation or the Krebs cycle (eg, fumarase deficiency) have to be considered as well.

Diagnostic workup

In many cases, a correct diagnosis will be made only if carnitine palmitoyltransferase II deficiency is specifically considered and appropriate tests are obtained.

Muscle form. Except during episodes of myoglobinuria, serum creatine kinase levels are usually normal. During acute episodes of rhabdomyolysis, laboratory findings are dominated by elevated urinary excretion of myoglobin and a significant increase in serum creatine kinase. There is no hypoglycemia, and ketonemia and ketonuria are appropriate.

Following attacks, serum creatine kinase levels usually return to normal by several weeks. Between attacks, routine laboratory tests are usually within normal limits and do not contribute to the diagnosis, except for elevated plasma triglyceride and cholesterol concentrations observed in some patients. Prolonged fasting at rest may result in delayed and reduced ketone body production or increased serum creatine kinase. EMG is sometimes described as generically "myopathic." MRI of muscles is normal or shows a mild increase of signal intensity in T1-weighted images (14). Biopsies taken shortly after an episode may show necrotic and regenerating fibers. Between exacerbations, muscle biopsies are normal in half of the patients and show nonspecific myopathic changes, such as slight lipid accumulation, in the other half (13).

During the symptom-free interval, tandem mass spectrometry of serum samples can frequently identify indirect evidence of carnitine palmitoyltransferase II deficiency by detecting an elevated ratio of C16 + C18:1/C2 (27; 13). Fatty acid oxidation studies in cultured fibroblast after incubation with palmitate can show elevation of C16/C2 ratio (12).

Despite the predominant muscular symptomatology, the enzyme deficiency can also be detected in fibroblasts and blood cells. It was shown that residual activity in blood leukocytes was similar to muscle activity (08). Although CPT II deficiency can be reliably measured in easily accessible blood samples, some laboratories prefer measurement in muscle (64); however, significantly different results have been obtained in normal and affected tissues, primarily related to the use of different assay conditions for measuring enzyme activity. When carnitine palmitoyltransferase is measured using the “forward assay” in muscle homogenate with optimal assay conditions, the measured activity includes both carnitine palmitoyltransferase I and II. Under these conditions, patients exhibit entirely normal total carnitine palmitoyltransferase activities. However, the enzyme activity of patients with muscle carnitine palmitoyltransferase II deficiency is abnormally inhibited in the presence of malonyl-coA, palmitoylcarnitine, and detergents such as Triton X-100 (68; 13). Thus, carnitine palmitoyltransferase II activity is not abolished in patients with muscle carnitine palmitoyltransferase II deficiency, but regulation of the enzyme is abnormal. This is consistent with a study showing that fatty acid oxidation in patients with the muscle form of carnitine palmitoyltransferase II deficiency is normal at rest, but impaired during exercise, and a study showing the normal protein content of carnitine palmitoyltransferase II in muscle (45; 39).

In patients with the muscle form of carnitine palmitoyltransferase II deficiency, rapid molecular genetic testing is possible because a common variant p.S113L is found on 60% to 70% of mutant alleles (58; 13). This variant was detected in 22 of 23 index cases (96%) on at least on one allele in German patients (13).

Multisystemic infantile and neonatal forms. In multisystemic carnitine palmitoyltransferase II deficiency, routine laboratory tests usually show evidence of hepatic insufficiency, hypoglycemia with low insulin levels and absent ketonemia or ketonuria, mild hyperammonemia, mild hyperlactacidemia, increased serum aspartate and alanine aminotransferases, elevated plasma free-fatty-acid concentrations, and prolonged prothrombin and partial thromboplastin times. Metabolic acidosis is often present, and serum creatine kinase may be elevated. Plasma and tissue levels of total carnitine are usually lowered (secondary carnitine deficiency) (08).

ECG and echocardiography can demonstrate the presence of dysrhythmias and dilated cardiomyopathy. Ultrasound analysis of the kidneys may reveal the presence of bilateral renal cysts, usually observed in neonatal-onset cases. Brain MRI studies may reveal malformations and other brain abnormalities, and MR spectroscopy may detect cerebral lipid accumulation (24).

Long-chain triglyceride loading fails to enhance ketogenesis and fasting shows a decline of blood glucose and low plasma ketone body values. A loading test with long-chain triglycerides (sunflower oil) given orally at the dose of 1.5 g/kg is safe, whereas a fasting test is potentially harmful and should be undertaken only in an intensive care unit under the close supervision of a trained specialist after the insertion of an intravenous line to permit immediate access for therapeutic quantities of glucose.

Tandem mass spectrometry is a rapid test to achieve indirect evidence of carnitine palmitoyltransferase II deficiency. It should be carried out in serum samples but can also be performed on dried blood spots (Guthrie cards) with lower sensitivity (01; 31; 11; 20; 57). Characteristically an elevated ratio of C16 + C18:1 is identified in patients with carnitine palmitoyltransferase II deficiency (01; 27). Palmitate oxidation in cultured fibroblasts is usually reduced to 10% to 20% of normal values but can be as low as 2% of control in the neonatal form.

Diagnosis is ultimately made by demonstrating the enzyme defect in the patients' tissue. In principle, all tissues can be examined. The lowest values were observed in neonatal-onset patients. Enzyme measurement that is available in specialized laboratories is mandatory only in rare cases in whom molecular genetic testing cannot detect biallelic pathogenic variants in CPT2. In clinical practice, diagnosis is commonly based on genetic testing.

Prenatal demonstration of carnitine palmitoyltransferase II deficiency is possible by measurement of impaired long-chain fatty acid oxidation and low carnitine palmitoyltransferase II activity in cultured amniocytes and sampled chorionic villi (65). In some families with the neonatal-onset form of the disease, fetal ultrasonography demonstrated renal abnormalities (eg, cyst) and brain abnormalities (eg, ventriculomegaly) (21). If both mutant alleles are known in the family, DNA extracted from fetal cells obtained by amniocentesis or chorionic villus sampling can be used for molecular genetic prenatal testing.

Management

Muscle form. To minimize the chances of developing acute tubular necrosis during acute episodes of myoglobinuria, patients should be promptly hydrated with forced diuresis.

Effective prevention of attacks may be accomplished by instituting a high-carbohydrate, low-fat diet with frequent and regularly scheduled meals, by avoiding the known precipitating factors (fasting, cold, prolonged exercise), and by increasing slow-release carbohydrate intake during intercurrent illness or sustained exercise. It was shown that ingestion of polysaccharides and glucose infusions can improve exercise intolerance but not oral glucose ingestion (46). Drugs that could trigger attacks such a valproate, diazepam, or ibuprofen should be avoided.

Regarding sporting activity, it was suggested to avoid endurance training. Based on physiological considerations, high intensity interval training should be preferred that is less dependent on fatty acid metabolism but more on glycogenolysis (43).

Studies with small sample sizes document some progress in finding effective treatment for carnitine palmitoyltransferase II deficiency. A small study with seven patients suffering from muscle carnitine palmitoyltransferase II deficiency investigated an anaplerotic diet with triheptanoin (triglyceride containing the odd-chain fatty acid C7). Patients no longer suffered recurrent attacks with rhabdomyolysis requiring hospitalization and returned to a normal lifestyle during treatment (49). A study in 32 patients with long-chain fatty acid oxidation disorders (including 10 patients with carnitine palmitoyltransferase II deficiency, mainly muscle form) showed improvement of cardiomyopathy (29). However, cardiomyopathy is not a typical sign of muscle carnitine palmitoyltransferase II deficiency.

In-vitro studies have shown that bezafibrate (known as a lipid-lowering drug) treatment of fibroblasts and myoblasts from patients with muscle carnitine palmitoyltransferase II deficiency can improve the biochemical defect by stimulating the expression of the mutated gene (18; 17). A pilot trial with bezafibrate treatment for 6 months in six patients with the muscle form of the disease showed an increase in the oxidation of palmitoyl-carnitine in muscle, an improvement of general health, and a decrease of muscle pain (06). Clinical benefits persisted in a follow up study of 3 years (05). No side effects were observed. This is particularly important because bezafibrate itself can induce rhabdomyolysis. However, a 3-month, randomized, double-blind, crossover study of bezafibrate in patients with muscle carnitine palmitoyltransferase II deficiency did not improve fatty acid oxidation or heart rate during exercise, indicating that bezafibrate has no meaningful effects in vivo (47). Another drug that showed upregulation of fatty acid oxidation in cells from patients with carnitine palmitoyltransferase 2 deficiency is resveratrol. However, a pilot study including five patients with muscle carnitine palmitoyltransferase deficiency did not observe enhanced exercise capacity or fatty acid oxidation (55). Thus, recommendations for drug treatment cannot be given.

Multisystemic infantile and neonatal forms. Experience in treating these forms is limited. It seems, however, that restriction of dietary long-chain fat is of primary importance because of the toxic effects of long-chain acylcarnitines that accumulate as a consequence of the metabolic block. In general, fasting has to be avoided, and patients should be given a diet high in carbohydrate and low in long-chain fat. Supplementation with medium-chain triglycerides can be considered (54). Episodes of hypoglycemia, especially when associated with intercurrent illness, require admission to the hospital and immediate intervention with parenteral glucose. In one neonatal case, glucose and insulin infusions resulted in spectacular clinical improvement (08).

References

01: Albers S, Marsden D, Quackenbush E, Stark AR, Levy HL, Irons M. Detection of neonatal carnitine palmitoyltransferase II deficiency by expanded newborn screening with tandem mass spectrometry. Pediatrics 2001;107(6):E103. PMID 11389301
02: Blanc PL, Carrier H, Thomas L, Chavaillon JM, Robert D. Acute rhabdomyolysis with carnitine-palmityl-transferase deficiency. Intensive Care Med 1982;8:307. PMID 7175018
03: Bo R, Musha I, Yamada K, et al. Need for strict clinical management of patients with carnitine palmitoyltransferase II deficiency: experience with two cases detected by expanded newborn screening. Mol Genet Metab Rep 2020;24:100611. PMID 32489884
04: Boemer F, Deberg M, Schoos R, et al. Diagnostic pitfall in antenatal manifestations of CPT II deficiency. Clin Genet 2016;89(2):193-7. PMID 25827434
05: Bonnefont JP, Bastin J, Laforet P, et al. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 2010;88(1):101-8. PMID 20505667
06: Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009;360:838-40. PMID 19228633
07: Bonnefont JP, Demaugre F, Prip-Buus C, et al. Carnitine palmitoyltransferase deficiencies. Mol Genet Metab 1999;68:424-40. PMID 10607472
08: Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferase 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 2004; 25:495-520. PMID 15363638
09: Bougneres PF, Saudubray JM, Marsac C, Bernard O, Odièvre M, Girard J. Fasting hypoglycemia resulting from hepatic carnitine palmitoyltransferase deficiency. J Pediatr 1981;98:742-6. PMID 7014807
10: Demaugre F, Bonnefont JP, Colonna M, Cepanec C, Leroux JP, Saudubray JM. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest 1991;87:859-64. PMID 1999498
11: de Sain-van der Velden MG, Diekman EF, et al. Differences between acylcarnitine profiles in plasma and bloodspots. Mol Genet Metab 2013;110(1-2):116-21. PMID 23639448
12: Deschauer M, Chrzanowska-Lightowlers ZMA, Biekmann E et al. A splice junction mutation in muscle carnitine palmitoyltransferase II deficiency. Mol Genet Metab 2003;79:124-8. PMID 12809643
13: Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: Clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005;62: 37-41. PMID 15642848
14: Diekman EF, van der Pol WL, Nievelstein RA, Houten SM, Wijburg FA, Visser G. Muscle MRI in patients with long-chain fatty acid oxidation disorders. J Inherit Metab Dis 2014;37(3):405-13. PMID 24305961
15: DiMauro S, Melis-DiMauro P. Muscle carnitine palmitoyltransferase deficiency and myoglobinuria. Science 1973;182:929-31. PMID 4745596
16: DiMauro S, Papadimitriou A. Carnitine palmitoyltransferase deficiency. In: Engel AG, Banker BQ, editors. Myology. New York: McGraw-Hill, 1986:1697-708.
17: Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab 2005;90:1791-7. PMID 15613406
18: Djouadi F, Bonnefont JP, Thuillier L, et al. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res 2003;54:446-51. PMID 12840153
19: Dreval D, Bernstein D, Zakut H. Carnitine palmitoyltransferase deficiency in pregnancy. A case report. Am J Obstet Gynecol 1994;170:1390-2. PMID 8178878
20: Edmondson AC, Salant J, Ierardi-Curto LA, Ficicioglu C. Missed newborn screening case of carnitine palmitoyltransferase-II deficiency. JIMD Rep 2017;33:93-7. PMID 27067077
21: Elpeleg ON, Hammerman C, Saada A, et al. Antenatal presentation of carnitine palmitoyltransferase II deficiency. Am J Med Genet 2001;102:183-7. PMID 11477613
22: Elpeleg ON, Joseph A, Branski D, et al. Recurrent metabolic decompensation in profound carnitine palmitoyltransferase II deficiency. J Pediatr 1993;122:917-9. PMID 8501570
23: Fanin M, Anichini A, Cassandrini D, et al. Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. Clin Genet 2012;82(3):232-9. PMID 21913903
24: Ferreira CR, Silber MH, Chang T, Murnick JG, Kirmse B. Cerebral lipid accumulation detected by MRS in a child with carnitine palmitoyltransferase 2 deficiency: a case report and review of the literature on genetic etiologies of lipid peaks on MRS. JIMD Rep 2016;28:69-74. PMID 26537576
25: Finocchiaro G, Taroni F, Rocchi M, et al. cDNA cloning, sequence analysis and chromosomal localization of human carnitine palmitoyltransferase [correction 10981]. Proc Natl Acad Sci USA 1991;88:661-5. PMID 1961767
26: Gellera C, Verderio E, Floridia G, et al. Assignment of the human carnitine palmitoyltransferase II gene (CPT1) to chromosome 1p32. Genomics 1994;24:195-7. PMID 7896283
27: Gempel K, Kiechl S, Hofmann S, et al. Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis 2002; 25:17-27. PMID 11999976
28: Gieron MA, Korthals JK. Carnitine palmityltransferase deficiency with permanent weakness. Pediatr Neurol 1987;3:51-3. PMID 3508048
29: Gillingham MB, Heitner SB, Martin J et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis 2017;40(6):831-43. PMID 28871440
30: Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. N Engl J Med 1991;325:1862-4. PMID 1961225
31: Illsinger S, Lücke T, Peter M, et al. Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screening. Am J Med Genet 2008; 146A:2925-8. PMID 18925671
32: Isackson PJ, Bennett MJ, Vladutiu GD. Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency. Mol Genet Metab 2006;89:323-31. PMID 16996287
33: Joshi PR, Deschauer M, Zierz S. Carnitine palmitoyltransferase II (CPT II) deficiency: genotype-phenotype analysis of 50 patients. J Neurol Sci 2014;338(1-2):107-11. PMID 24398345
34: Joshi PR, Deschauer M, Zierz S. Clinically symptomatic heterozygous carnitine palmitoyltransferase II (CPT II) deficiency. Wien Klin Wochenschr 2012;124(23-24):851-4. PMID 23184072
35: Joshi PR, Deschauer M, Zierz S. Phenotype of carnitine palmitoyltransferase II (CPT II) deficiency: a questionnaire-based survey. J Clin Neurosci 2019;59:32-6. PMID 30455135
36: Katsuya H, Misumi M, Ohtani Y, Miike T. Postanesthetic acute renal failure due to carnitine palmitoyltransferase deficiency. Anesthesiology 1988;68(6):945-8. PMID 3256299
37: Kelly KJ, Garland JS, Tangl TT, Shug AL, Chusid MJ. Fatal rhabdomyolysis following influenza infection in a girl with familial carnitine palmitoyltransferase deficiency. Pediatrics 1989;84:312-6. PMID 2748260
38: Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lucking CH. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 2001;11:757-9. PMID 11595519
39: Lehmann D, Zierz S. Normal protein content but abnormally inhibited enzyme activity in muscle carnitine palmitoyltransferase II deficiency. J Neurol Sci 2014;339(1-2):183-8. PMID 24602495
40: Lindner M, Bettendorf M, Hoffmann GF. Fachinformation Neugeborenenscreening 2008.
41: Martin MA, Rubio JC, de Bustos F, et al. Molecular analysis in Spanish patients with muscle carnitine palmitoyltransferase deficiency. Muscle Nerve 1999;22:941-3. PMID 10398215
42: Martinez G, Ribes A, Garavaglia B, et al. Favourable clinical evolution in a 20-year old girl with the infantile form of carnitine palmitoyltransferase II deficiency. In: 7th International congress of Inborn Errors of Metabolism, Vienna, 21-25 May 1997, Abstract O101
43: Negro M, Giuseppe Cerullo G, Parimbelli M, et al. Exercise, nutrition, and supplements in the muscle carnitine palmitoyl-transferase II deficiency: new theoretical bases for potential applications. Front Physiol 2021;12:704290.** PMID 34408664
44: Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-8. PMID 7904009
45: Orngreen MC, Duno M, Ejstrup R et al. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutation. Ann Neurol 2005;57:60-66. PMID 15622536
46: Orngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology. 2003;61:559-61. PMID 12939440
47: Orngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforet P. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology 2014;82(7):607-13. PMID 24453079
48: Ramsey PS, Biggio JR. Carnitine palmitoyltransferase deficiency in pregnancy. J Matern Fetal Neonatal Med 2005;18:357-9. PMID 16390799
49: Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, Garritson BK. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 2008;71:260-4. PMID 18645163
50: Ross NS, Hoppel CL. Partial muscle carnitine palmitoyltransferase-A deficiency. Rhabdomyolysis associated with transiently decreased muscle carnitine content after ibuprofen therapy. JAMA 1987;257:62-65. PMID 3783904
51: Rouyer A, Tard C, Dessein AF, et al. Long-term prognosis of fatty-acid oxidation disorders in adults: Optimism despite the limited effective therapies available. Eur J Neurol 2024;31(2):e16138. PMID 38015438
52: Slater PM, Grivell R, Cyna AM. Labour management of a woman with carnitine palmitoyl transferase type 2 deficiency. Anaesth Intensive Care 2009;37:305-8. PMID 19400498
53: Smolle KH, Kaufmann P, Gasser R. Recurrent rhabdomyolysis and acute respiratory failure due to carnitine palmityltransferase deficiency. Intensive Care Med 2001;27:1235. PMID 11534575
54: Spiekerkoetter U, Lindner M, Santer R et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 2009;32(4):498-505. PMID 19452263
55: Storgaard JH, Løkken N, Madsen KL, et al. No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: a randomized clinical cross-over trial. J Inherit Metab Dis 2022;45:517-28. PMID 35066899
56: Taggart RT, Smail D, Apolito C, Vladutiu GD. Novel mutations associated with carnitine palmitoyltransferase II deficiency. Hum Mutat 1999;13:210-20. PMID 10090476
57: Tajima G, Hara K, Tsumura M, et al. Newborn screening for carnitine palmitoyltransferase II deficiency using (C16+C18:1)/C2: evaluation of additional indices for adequate sensitivity and lower false-positivity. Mol Genet Metab 2017;122(3):67-75. PMID 28801073
58: Taroni F, Verderio E, Dworzak F, Willems PJ, Cavadini P, DiDonato S. Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat Genet 1993;4:314-20. PMID 8358442
59: Taroni F, Verderio E, Fiorucci S, et al. Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl Acad Sci USA 1992a;89:8429-33. PMID 1528846
60: Tein I, DiMauro S, DeVivo DC. Recurrent childhood myoglobinuria. Adv Pediatr 1990;37:77-117. PMID 2264536
61: Thuillier L, Rostane H, Droin V, et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency. Hum Mutat 2003;21:493-501. PMID 12673791
62: Thuillier L, Sevin C, Demaugre F et al. Genotype/phenotype correlation in carnitine palmitoyl transferase II deficiency: lessons from a compound heterozygous patient. Neuromuscul Disord 2000;10:200-5. PMID 10734268
63: Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990;27:181-5. PMID 2156480
64: Tucci S, Behringer S, Sturm M, Grünert SC, Spiekerkoetter U. Implementation of a fast method for the measurement of carnitine palmitoyltransferase 2 activity in lymphocytes by tandem mass spectrometry as confirmation for newborn screening. J Inherit Metab Dis 2019;42:850-6. PMID 30957255
65: Vekemans BC, Bonnefont JP, Aupetit J, et al. Prenatal diagnosis of carnitine palmitoyltransferase 2 deficiency in chorionic villi: a novel approach. Prenat Diagn 2003;23:884-7. PMID 14634971
66: Vladutiu GD, Hogan K, Saponara I, Tassini L, Conroy J. Carnitine palmitoyltransferase deficiency in malignant hyperthermia. Muscle Nerve 1993;16:485-91. PMID 8515756
67: Vladutiu GD, Quackenbush EJ, Hainline BE, et al. Lethal neonatal and severe late infantile forms of carnitine palmitoyltransferase II deficiency associated with compound heterozygosity for different protein truncation mutations. J Pediatr 2002;141:734-6. PMID 12410208
68: Wieser T, Deschauer M, Olek K, Hermann T, Zierz S. Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients. Neurology 2003;60:1354-6. PMID 12707442
69: Woeltje KF, Esser V, Weis BC, et al. Inter-tissue and inter-species characteristics of the mitochondrial carnitine palmitoyltransferase enzyme system. J Biol Chem 1990;265:10714-9. PMID 2355017
70: Yamamoto T, Tanaka H, Kobayashi H, et al. Retrospective review of Japanese sudden unexpected death in infancy: the importance of metabolic autopsy and expanded newborn screening. Mol Genet Metab 2011;102(4):399-406. PMID 21227726
71: Yasuno T, Kaneoka H, Tokuyasu T, et al. Mutations of carnitine palmitoyltransferase II (CPT II) in Japanese patients with CPT II deficiency. Clin Genet 2008;73(5):496-501. PMID 18363739
72: Zierz S. Carnitine palmitoyltransferase deficiency. In: Engel AG, Franzini-Armstrong C, editors. Myology 2nd ed. New York: McGraw-Hill, 1994:1577-86.
73: Zierz S, Schmitt U. Inhibition of carnitine palmitoyltransferase by malonyl-CoA in human muscle is influenced by anesthesia. Anesthesiology 1989;70:373. PMID 2913880

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Marcus Deschauer MD

Dr. Deschauer of Technical University of Munich received honorariums from Genzyme, Biogen, and Roche for service as guest speaker, consultant, and advisory board member.
See Profile

Editor

Deepa S Rajan MD

Dr. Rajan of UPMC Children's Hospital of Pittsburgh has no relevant financial relationships to disclose.
See Profile

Former Authors

Franco Taroni MD
Darryl De Vivo MD

Patient Profile

Age range of presentation: 0 month to 64 years
Sex preponderance: male>female, >1:1
Heredity: heredity may be a factor

heredity typical

autosomal recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD: ICD: 9

Disorders of fatty acid oxidation: 277.85
ICD-10: Myopathy in metabolic disease: G73.6

Other lipid storage disorders: E75.5
OMIM: Carnitine palmitoyltransferase II deficiency, myopathic: #255110

Carnitine palmitoyltransferase II deficiency, infantile: #600649

Carnitine palmitoyltransferase II deficiency, lethal neonatal: #608836

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Carnitine palmitoyltransferase II deficiency

Associated Disorders

Acute renal failure
Cardiomyopathy
Coma
Hepatic failure
Myoglobinuria
- Renal cystic dysplasia
- Renal tubular acidosis
- Rhabdomyolysis

Differential Diagnosis

myoglobinuria
exercise-induced myalgia
strenuous exercise
chronic alcoholism
toxic agents
- statins
- fibrates
- infections
- trauma
- other genetic diseases
- muscular dystrophy
- malignant hyperthermia
- myophosphorylase deficiency
- glycogenosis type V
- glycogen metabolism
- glycolysis
- very-long-chain acyl-CoA dehydrogenase deficiency
- exercise-induced rhabdomyolysis
- mutations in mitochondrial DNA
- coenzyme Q deficiency
- other genetic defects of fatty-acid oxidation
- hypoketotic hypoglycemia
- heart and skeletal-muscle involvement
- deficiency of carnitine
- carnitine and acylcarnitine translocase
- trifunctional protein
- short-chain 3-hydroxyacyl-CoA dehydrogenase
- multiple acyl-CoA dehydrogenase deficiency
- other multisystemic mitochondrial disorders

Also Relevant

Carnitine palmitoyltransferase 1A deficiency
Carnitine-acylcarnitine translocase deficiency
Long-chain fatty acid oxidation defects
Multiple acyl-CoA dehydrogenase deficiency
Myoglobinuria
- Primary carnitine transporter deficiency

Clinical Categories

Neurogenetic Disorders

Carnitine palmitoyltransferase II deficiency

Carnitine palmitoyltransferase II deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Vanishing white matter disease

Wilson disease

White matter abnormalities in the brain

Hypermethioninemia

POLG-related mitochondrial disorders

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

Carnitine palmitoyltransferase II deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Vanishing white matter disease

Wilson disease

White matter abnormalities in the brain

Hypermethioninemia

POLG-related mitochondrial disorders

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

This is an article preview.
Start a Free Account
to access the full version.